1. Home
  2. SNWV vs GNFT Comparison

SNWV vs GNFT Comparison

Compare SNWV & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNWV
  • GNFT
  • Stock Information
  • Founded
  • SNWV 2004
  • GNFT 1999
  • Country
  • SNWV United States
  • GNFT France
  • Employees
  • SNWV N/A
  • GNFT N/A
  • Industry
  • SNWV
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SNWV
  • GNFT Health Care
  • Exchange
  • SNWV NYSE
  • GNFT Nasdaq
  • Market Cap
  • SNWV 234.2M
  • GNFT 214.5M
  • IPO Year
  • SNWV N/A
  • GNFT 2019
  • Fundamental
  • Price
  • SNWV $33.30
  • GNFT $3.93
  • Analyst Decision
  • SNWV
  • GNFT Strong Buy
  • Analyst Count
  • SNWV 0
  • GNFT 1
  • Target Price
  • SNWV N/A
  • GNFT $13.00
  • AVG Volume (30 Days)
  • SNWV 63.4K
  • GNFT 3.3K
  • Earning Date
  • SNWV 08-11-2025
  • GNFT 04-24-2025
  • Dividend Yield
  • SNWV N/A
  • GNFT N/A
  • EPS Growth
  • SNWV N/A
  • GNFT N/A
  • EPS
  • SNWV N/A
  • GNFT 0.03
  • Revenue
  • SNWV $36,190,000.00
  • GNFT $73,187,701.00
  • Revenue This Year
  • SNWV N/A
  • GNFT $15.98
  • Revenue Next Year
  • SNWV N/A
  • GNFT N/A
  • P/E Ratio
  • SNWV N/A
  • GNFT $124.79
  • Revenue Growth
  • SNWV 61.50
  • GNFT 105.01
  • 52 Week Low
  • SNWV $5.18
  • GNFT $2.55
  • 52 Week High
  • SNWV $39.50
  • GNFT $6.42
  • Technical
  • Relative Strength Index (RSI)
  • SNWV N/A
  • GNFT 42.09
  • Support Level
  • SNWV N/A
  • GNFT $4.03
  • Resistance Level
  • SNWV N/A
  • GNFT $4.61
  • Average True Range (ATR)
  • SNWV 0.00
  • GNFT 0.12
  • MACD
  • SNWV 0.00
  • GNFT -0.05
  • Stochastic Oscillator
  • SNWV 0.00
  • GNFT 0.00

About SNWV SANUWAVE HEALTH INC

SANUWAVE Health Inc is an ultrasound and shock wave technology company using patented systems of noninvasive, high-energy, acoustic shock waves or low-intensity and non-contact ultrasound for regenerative medicine and other applications. The company's focus is regenerative medicine utilizing noninvasive, acoustic shock waves or ultrasound to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's two primary systems are UltraMIST and PACE. UltraMIST and PACE are the only two Food and Drug Administration (FDA) approved directed energy systems for wound healing.

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Share on Social Networks: